APA

Shamriz O., Simon A. J., Lev A., Megged O., Ledder O., Picard E., Joseph L., Molho-Pessach V., Tal Y., Millman P., Slae M., Somech R., Toker O. & Berger M. (20201013). Exogenous interleukin-2 can rescue in-vitro T cell activation and proliferation in patients with a novel capping protein regulator and myosin 1 linker 2 mutation. : Clinical and experimental immunology.

Chicago

Shamriz O, Simon A J, Lev A, Megged O, Ledder O, Picard E, Joseph L, Molho-Pessach V, Tal Y, Millman P, Slae M, Somech R, Toker O and Berger M. 20201013. Exogenous interleukin-2 can rescue in-vitro T cell activation and proliferation in patients with a novel capping protein regulator and myosin 1 linker 2 mutation. : Clinical and experimental immunology.

Harvard

Shamriz O., Simon A. J., Lev A., Megged O., Ledder O., Picard E., Joseph L., Molho-Pessach V., Tal Y., Millman P., Slae M., Somech R., Toker O. and Berger M. (20201013). Exogenous interleukin-2 can rescue in-vitro T cell activation and proliferation in patients with a novel capping protein regulator and myosin 1 linker 2 mutation. : Clinical and experimental immunology.

MLA

Shamriz O, Simon A J, Lev A, Megged O, Ledder O, Picard E, Joseph L, Molho-Pessach V, Tal Y, Millman P, Slae M, Somech R, Toker O and Berger M. Exogenous interleukin-2 can rescue in-vitro T cell activation and proliferation in patients with a novel capping protein regulator and myosin 1 linker 2 mutation. : Clinical and experimental immunology. 20201013.